Reuters logo
BRIEF-Lexicon Pharmac reports positive late-stage data on diabetes drug
2017年6月9日 / 上午11点20分 / 3 个月前

BRIEF-Lexicon Pharmac reports positive late-stage data on diabetes drug

June 9 (Reuters) - Lexicon Pharmaceuticals Inc-

* Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes

* Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes

* Lexicon Pharmaceuticals Inc - ‍study met its primary endpoint​

* Sotagliflozin demonstrated a generally well tolerated safety profile during a 24-week treatment period

* Lexicon Pharmaceuticals Inc - sotagliflozin demonstrates statistically significant benefit in primary endpoint

* Lexicon Pharmaceuticals Inc - results support a unique drug profile as an sglt1 and sglt2 inhibitor Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below